Literature DB >> 16857268

Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis.

Neli Boneva1, Melinee Frenkian-Cuvelier, Jocelyne Bidault, Talma Brenner, Sonia Berrih-Aknin.   

Abstract

MG with anti-MuSK antibodies (MuSK+) is often characterized with muscle atrophy and excellent response to plasma exchanges. To elucidate some MuSK+ MG features, we analyzed the functional effects of anti-MuSK Abs in human TE 671 muscle cells. We found that some MuSK+ sera induced a striking inhibition of proliferation, accompanied by: 1) cell cycle arrest, 2) atrogin-1 overexpression, 3) AChR subunits, rapsyn, Rho A and cdc42 downregulation. These effects correlated to disease severity and to anti-MuSK Abs titer and vanished following PE. Altogether, these results indicate that anti-MuSK Abs could be pathogenic by contributing to the muscle atrophy in MuSK+ MG patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857268     DOI: 10.1016/j.jneuroim.2006.05.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.

Authors:  Alexandra Pevzner; Benedikt Schoser; Katja Peters; Nicoleta-Carmen Cosma; Andromachi Karakatsani; Berthold Schalke; Arthur Melms; Stephan Kröger
Journal:  J Neurol       Date:  2011-08-05       Impact factor: 4.849

Review 2.  Anti-MuSK ocular myasthenia with extrinsic ocular muscle atrophy: a new clinical phenotype?

Authors:  Dario Ricciardi; Vincenzo Todisco; Gioacchino Tedeschi; Giovanni Cirillo
Journal:  Neurol Sci       Date:  2019-08-17       Impact factor: 3.307

3.  Anti-MuSK autoantibodies block binding of collagen Q to MuSK.

Authors:  Y Kawakami; M Ito; M Hirayama; K Sahashi; B Ohkawara; A Masuda; H Nishida; N Mabuchi; A G Engel; K Ohno
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

4.  [Neuromuscular signal transmission in adulthood. Current facets of acquired and hereditary disorders].

Authors:  A Abicht; S Kröger; B Schoser
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

5.  Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice.

Authors:  R N Cole; N Ghazanfari; S T Ngo; O L Gervásio; S W Reddel; W D Phillips
Journal:  J Physiol       Date:  2010-07-05       Impact factor: 5.182

Review 6.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

7.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

8.  Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis.

Authors:  Nobuhiro Sawa; Hiroshi Kataoka; Nobuyuki Eura; Satoshi Ueno
Journal:  BMJ Case Rep       Date:  2013-01-31

9.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

Review 10.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.